| 24613930 |
Identification of the transforming STRN-ALK fusion as a potential therapeutic target in the aggressive forms of thyroid cancer
Altschuler, DL,
Nikiforov, YE,
Ferris, RL,
Hodak, SP,
Liu, P,
Kelly, LM,
Nikiforova, MN,
Yu, YP,
Dacic, S,
Trivedi, S,
Luo, J,
Barila, G,
Panebianco, F,
Gandhi, M,
Carty, SE,
Evdokimova, VN
|
Proc Natl Acad Sci U S A |
2014 |
| 28404650 |
Identification of a novel crizotinib-sensitive BCL11A-ALK gene fusion in a nonsmall cell lung cancer patient
Li, ZW,
Deng, WJ,
Tian, Q
|
Eur Respir J |
2017 |
| 26301689 |
RAS-MAPK dependence underlies a rational polytherapy strategy in EML4-ALK-positive lung cancer
Okimoto, RA,
Rosell, R,
Aisner, DL,
Collisson, EA,
Doebele, RC,
Vaishnavi, A,
Riess, JW,
Lovly, CM,
Blakely, CM,
Olivas, V,
Ou, SH,
Sabnis, A,
Bivona, TG,
Karachaliou, N,
Tulpule, A,
Lin, L,
Hrustanovic, G,
Flanagan, J,
Mack, PC,
Ichihara, E,
Chan, E,
Asthana, S,
Varella-Garcia, M,
Neel, DS,
Pazarentzos, E
|
Nat Med |
2015 |
| 22570254 |
Identification of anaplastic lymphoma kinase as a potential therapeutic target in ovarian cancer
Haack, H,
Ren, JM,
Gu, TL,
Zhu, X,
Innocenti, G,
Crosby, K,
Tan, ZP,
Moritz, A,
Yang, YF,
Ren, H,
Rush, J,
Beausoleil, S,
Comb, MJ,
Zhang, Y,
Zhou, XM
|
Cancer Res |
2012 |
| 24496003 |
HIP1-ALK, a novel ALK fusion variant that responds to crizotinib
Wang, Z,
Christensen, J,
Zhang, C,
Mao, M,
Li, J,
Sun, H,
Ozeck, M,
Fang, DD,
Chan, CC,
Chen, X,
Gu, Q,
Sheng, W,
Chen, KX,
Qian, M,
Zhang, B,
Xu, Q,
Lira, M,
Chen, SH
|
J Thorac Oncol |
2014 |
| 20979473 |
EML4-ALK mutations in lung cancer that confer resistance to ALK inhibitors
Ishikawa, Y,
Soda, M,
Ueno, T,
Choi, YL,
Yamashita, Y,
Kimura, H,
Takashima, J,
Tanio, Y,
Nakajima, T,
Hamada, T,
ALK Lung Cancer Study Group, -,
Mitsudomi, T,
Yatabe, Y,
Haruta, H,
Takeuchi, K,
Mano, H
|
N. Engl. J. Med. |
2010 |
| 27245569 |
Comprehensive Genomic Profiling Identifies a Subset of Crizotinib-Responsive ALK-Rearranged Non-Small Cell Lung Cancer Not Detected by Fluorescence In Situ Hybridization
Ganesan, S,
Hensing, T,
Nowak, J,
Ou, SH,
Allen, J,
Ross, JS,
Wakelee, H,
Schrock, AB,
He, J,
Zakowski, M,
Frampton, GM,
Gowen, K,
Miller, VA,
Menon, S,
Chmielecki, J,
Ladanyi, M,
Molina, JR,
Zauderer, M,
Klempner, SJ,
Peled, N,
Firozvi, K,
Ali, SM,
Stephens, PJ,
Fischbach, N,
MacMahon, H,
Lipson, D,
Suh, JH,
Sanford, E,
Salgia, R,
Elvin, JA,
Chalmers, Z,
Brahmer, JR,
Yelensky, R,
Kulkarni, A
|
Oncologist |
2016 |
| 25393796 |
Identification of a novel HIP1-ALK fusion variant in Non-Small-Cell Lung Cancer (NSCLC) and discovery of ALK I1171 (I1171N/S) mutations in two ALK-rearranged NSCLC patients with resistance to Alectinib
Azada, M,
Klempner, SJ,
Schrock, AB,
Ali, SM,
Ou, SH,
Stephens, PJ,
Miller, VA,
Ross, JS,
Greenbowe, JR
|
J Thorac Oncol |
2014 |
| 25421750 |
Treatment Efficacy and Resistance Mechanisms Using the Second-Generation ALK Inhibitor AP26113 in Human NPM-ALK-Positive Anaplastic Large Cell Lymphoma
Piazza, R,
Ceccon, M,
Giudici, G,
Mologni, L,
Fontana, D,
Gambacorti-Passerini, C,
Pirola, A
|
Mol. Cancer Res. |
2015 |
| 26001147 |
BIRC6-ALK, a Novel Fusion Gene in ALK Break-Apart FISH-Negative Lung Adenocarcinoma, Responds to Crizotinib
Ying, J,
Zeng, Y,
Wu, J,
Xu, F,
Zhang, W,
Jiao, Y,
Jiang, P,
Guo, L,
Shan, L
|
J Thorac Oncol |
2015 |
| 24518094 |
HIP1-ALK, a novel fusion protein identified in lung adenocarcinoma
Kim, RN,
Choi, YL,
Song, JY,
Han, J,
Takeuchi, K,
Mao, M,
Kim, J,
Oh, E,
Lira, ME,
Choi, SJ,
Hong, M
|
J Thorac Oncol |
2014 |
| 31388026 |
Molecular Modeling of ALK L1198F and/or G1202R Mutations to Determine Differential Crizotinib Sensitivity
Chang, HW,
Yang, CN,
Chuang, YC,
Huang, BY
|
Sci Rep |
2019 |
| 21502504 |
Therapeutic strategies to overcome crizotinib resistance in non-small cell lung cancers harboring the fusion oncogene EML4-ALK
Khan, TM,
Iafrate, AJ,
Shakespeare, WC,
Shaw, AT,
Lifshits, E,
Rivera, VM,
Ebi, H,
Engelman, JA,
Benes, C,
Katayama, R
|
Proc. Natl. Acad. Sci. U.S.A. |
2011 |
